Table 58Adverse events associated with local hepatic therapies: TACE compared with TEA (TAE)

Study
Rating
Design
Treatment Group
N
InterventionLiver Failure %Hepatic Hemorrhage %Hepatic Abscess %Rare AE, N (%)
Yu et al. 200963
Poor
Retrospective case control
TACE
30
TACE with lipiodol (20mL) - cisplatin (10mg) emulsion and gelatin sponge particle embolization via hepatic artery for a median of 3 treatmentsNRNRNRNR
TEA
30
TEA with lipiodol-ethanol mixture (mean: 14.5mL, SD: 17.6mL) via tumor feeder vessel(s) for a median of 2 treatmentsNRNRNRNR

Abbreviations: AE = adverse event; N = number of patients; NR = not reported; SD = standard deviation; TACE = transarterial chemoembolization; TEA = transarterial ethanol ablation.

From: Results

Cover of Local Therapies for Unresectable Primary Hepatocellular Carcinoma
Local Therapies for Unresectable Primary Hepatocellular Carcinoma [Internet].
Comparative Effectiveness Reviews, No. 114.
Belinson S, Yang Y, Chopra R, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.